STOCK TITAN
  1. Home
  2. Sec-filings
  3. AXSM
  4. [Form 4] Axsome Therapeutics, Inc. Insider Trading Activity

Axsome (NASDAQ: AXSM) awards 7,224 PSUs to its general counsel

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Murdock Hunter R. reported acquisition or exercise transactions in this Form 4 filing.

Axsome Therapeutics, Inc. reported that its General Counsel, Hunter R. Murdock, received a grant of 7,224 Performance Stock Units (PSUs). Each PSU represents a contingent right to receive one share of Axsome common stock. The PSUs will vest only if specified sales and commercial launch milestones are achieved and if the executive continues in service through each vesting date. Following this award, Murdock holds 7,224 PSUs directly.

Positive

  • None.

Negative

  • None.
Insider Murdock Hunter R.
Role General Counsel
Type Security Shares Price Value
Grant/Award Performance Stock Units 7,224 $0.00 --
Holdings After Transaction: Performance Stock Units — 7,224 shares (Direct, null)
Footnotes (1)
  1. Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date.
PSUs granted 7,224 units Performance Stock Units awarded to General Counsel
Exercise/award price $0.0000 per unit Reported transaction price per Performance Stock Unit
PSUs following transaction 7,224 units Total Performance Stock Units held after grant
Underlying common shares 7,224 shares Each PSU corresponds to one share of common stock
Performance Stock Units financial
"Each performance stock unit ("PSU") represents a contingent right to receive one share"
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
contingent right financial
"represents a contingent right to receive one share of the Issuer's common stock"
vesting date financial
"subject to the reporting person's continued service as of each vesting date"
sales and commercial launch milestones financial
"will vest upon achievement of certain sales and commercial launch milestones"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Murdock Hunter R.
(Last)(First)(Middle)
C/O AXSOME THERAPEUTICS, INC.
ONE WORLD TRADE CENTER, 29TH FLOOR
(Street)
NEW YORK NEW YORK 10007
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Axsome Therapeutics, Inc. [ AXSM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
General Counsel
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Stock Units(1)04/21/2026A7,224 (2) (2)Common Stock7,224$07,224D
Explanation of Responses:
1. Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.
2. Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date.
/s/ Hunter Murdock04/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Axsome Therapeutics (AXSM) report for Hunter R. Murdock?

Axsome reported that General Counsel Hunter R. Murdock received a grant of 7,224 Performance Stock Units. These units are part of his equity compensation and give him a contingent right to receive Axsome common shares if vesting conditions are satisfied.

How many Performance Stock Units did the Axsome (AXSM) general counsel receive?

Hunter R. Murdock received 7,224 Performance Stock Units. After this grant, his total reported holdings in these PSUs are 7,224 units, each linked to one share of Axsome common stock upon vesting, assuming all conditions are ultimately met.

What does each Performance Stock Unit represent for Axsome (AXSM) insiders?

Each Axsome Performance Stock Unit represents a contingent right to receive one share of the company’s common stock. The insider does not receive the share immediately; settlement occurs only if the PSU’s vesting conditions are later fulfilled as described in the award terms.

What are the vesting conditions for the Axsome (AXSM) PSUs granted to the general counsel?

The PSUs will vest upon achievement of specified sales and commercial launch milestones, subject to continued service. This means vesting requires both business performance targets and that Hunter R. Murdock remains in his role through each applicable vesting date.

Was the Axsome (AXSM) Form 4 transaction a market purchase or sale of stock?

No. The Form 4 shows a grant of Performance Stock Units as compensation, not an open-market stock purchase or sale. The transaction code is “A,” indicating an award or other acquisition, with no cash price per share reported for the derivative grant.